Sulfonylurea drugs, such as glibenclamide, that inhibit Kir6.2/SUR1 have been used clinically for decades to treat type 2 diabetes due to their ability to stimulate insulin secretion and lower blood glucose (Kharade et al., 2016; Nichols, 2023). This evidence concerns the gene ABCC8 and type 2 diabetes mellitus.